Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Free Cash Flow (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Free Cash Flow readings, the most recent being -$1.6 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 53.96% to -$1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.5 million, a 61.18% increase, with the full-year FY2025 number at -$5.5 million, up 61.18% from a year prior.
  • Free Cash Flow hit -$1.6 million in Q4 2025 for Sunshine Biopharma, down from -$735840.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$297355.0 in Q1 2021 to a low of -$5.6 million in Q2 2024.
  • Median Free Cash Flow over the past 5 years was -$1.5 million (2025), compared with a mean of -$1.8 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 858.16% in 2021 and later surged 74.18% in 2025.
  • Sunshine Biopharma's Free Cash Flow stood at -$312113.0 in 2021, then plummeted by 681.96% to -$2.4 million in 2022, then rose by 5.46% to -$2.3 million in 2023, then crashed by 52.03% to -$3.5 million in 2024, then soared by 53.96% to -$1.6 million in 2025.
  • The last three reported values for Free Cash Flow were -$1.6 million (Q4 2025), -$735840.0 (Q3 2025), and -$1.4 million (Q2 2025) per Business Quant data.